“…Of additional notice, although CBZ is safe and effective in anti-convulsant activities, the unwanted events following CBZ treatment, such as hyponatremia, QT-interval prolongation, hyperprolactinemia, change in pitch perception and idiosyncratic reactions, have gradually emerged [ 5 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 ]. The effectiveness of CBZ in inhibiting the activity of ATP-sensitive K + (K ATP ) channels has also been demonstrated [ 29 , 30 ]. However, this drug was reported to restore neuronal signaling, protein synthesis, and cognitive function in a mouse model of fragile X syndrome [ 31 ] as well as to improve motor impairment either in myotonia congenita or in the model of Machado-Joseph disease [ 9 , 10 ].…”